Dark
Streaming/Mobile
OldĀ Site
Home
Products
Help
Contact Us
Your Account
System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
16:58:16 EDT Thu 02 May 2024
Quotes
Streaming/Mobile
Quick Quotes (x20)
Symbol Search
Company Search
Market Depth
US Options
Montreal Options
Foreign Exchange
Download Close Prices
Short History
Quotes Help
Charts
12 Month Chart
Advanced Chart
Live Intraday Chart
Live Historical Chart
Live Java Intraday Chart
Live Java Historical Chart
Charts Help
News
News Search
SEDAR Search
SEDAR Alerts
News Help
Indexes
Major Indexes
US incl Dow Jones
NASDAQ
S&P CME
PBOT - Phil Ex
TSX - Toronto
TSX-V - TSX Venture
Indexes Help
Portfolio
View Portfolio
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
Value Portfolio
All Portfolios
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
Edit Portfolio
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
Chart Portfolio
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
Live Portfolio
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
View Portfolio News
Daily Summary
Portfolio Help
Analytics
Exchange Statistics
Most Active
Live Most Active
Block Trades
Broker Trades
Halted Stocks
Dividends
Participants
Companies
Trade Workstation
Company Picker
Short Positions
Broker Codes
Analytics Help
Mutual Funds
Mutual Fund Search
Targeted Holder Search
SEDAR Fund Search
Mutual Fund Help
Enter Symbol
or Name
USA
CA
Quote
Chart
News
Closes
Depth
Forgot password?
Trouble logging in?
Login to Stockwatch
Q:ADAP
- ADAPTIMMUNE THERAPEUTICS PLC SPON ADS EACH REP 6 ORD SHS -
http://www.adaptimmune.com
16:58:16 EDT
Sym-X
Bid - Ask
Last
Chg
%Ch
Vol
$Vol
#Tr
Open-Hi-Lo
Year Hi-Lo
Last Tr
News
Delay
ADAP
- Q
0.2
1.18
·
1.22
20.5
1.19
-0.02
-1.7
716.1
814
953
1.25
1.25
1.17
2.05 0.42
16:00:03
May 01
15 min
RT 2¢
Trade times are ET. News times are ET. Bid/ask/vol sizes in thousands.
Nasdaq Indicators -- Market:
Nasdaq
-- Bid Tick:
Down
-- UPC Restricted:
No
Fundamentals
·
Holders
·
Trade Workstation
·
Market Depth
·
3 Month Closes
·
Technical Charts
1 yr
|
2 yr
|
3 yr
|
5 yr
|
10 yr
|
15 yr
|
20 yr
·
Live Charts
1 yr
|
1 day
·
1yr Bulletins
·
Historical
·
Options
·
Portfolio
Recent Trades - Last 10 of 953
More trades...
Time ET
Ex
Price
Change
Volume
16:00:03
Q
1.19
-0.02
100
16:00:03
Q
1.19
-0.02
4,463
16:00:03
Q
1.19
-0.02
1,800
16:00:03
Q
1.19
-0.02
4
16:00:03
Q
1.19
-0.02
125
16:00:03
Q
1.19
-0.02
10
16:00:03
Q
1.19
-0.02
32
16:00:03
Q
1.19
-0.02
6
16:00:03
Q
1.19
-0.02
1
16:00:03
Q
1.19
-0.02
125
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
Recent Bulletins
News Releases
In The News
Other
Date ET
Symbol
Type
Headline
2024-05-01 12:01
U:ADAP
News Release
200
Adaptimmune to Report Q1 2024 Financial and Business Updates on Wednesday, May 15, 2024
2024-04-12 08:01
U:ADAP
News Release
200
Strategic Collaboration between Adaptimmune and Genentech to Research, Develop, and Commercialize Cancer-targeted Allogeneic T-cell Therapies Terminated
2024-03-27 19:31
U:ADAP
News Release
200
Results of Adaptimmune's SPEARHEAD-1 Trial with Afami-cel in Advanced Sarcomas Published in the Lancet
2024-03-06 07:01
U:ADAP
News Release
200
Adaptimmune Reports Q4/Full Year 2023 Financial Results and Business Updates
2024-02-27 08:02
U:ADAP
News Release
200
Adaptimmune Hires Chief Commercial Officer in Advance of Q3 2024 PDUFA Date for Afami-cel, a Late-stage Product in the Company's Sarcoma Franchise
2024-02-21 16:02
U:ADAP
News Release
200
Adaptimmune to Report Q4 and Full Year 2023 Financial and Business Updates on Wednesday, March 6, 2024
2024-01-31 16:45
U:ADAP
News Release
200
Adaptimmune Announces U.S. FDA Acceptance of Biologics License Application for Afami-cel for the Treatment of Advanced Synovial Sarcoma with Priority Review
2024-01-04 07:38
U:ADAP
News Release
200
Adaptimmune Projects Sarcoma Franchise to Deliver US Peak Year Sales up to $400 Million - Presentation at JP Morgan Healthcare Conference
2023-12-06 07:01
U:ADAP
News Release
200
Adaptimmune Completes Submission of Rolling Biologics License Application (BLA) to U.S. FDA for Afami-cel for the Treatment of Advanced Synovial Sarcoma
2023-11-29 08:01
U:ADAP
News Release
200
Adaptimmune Receives Transfer of IND for Lete-cel Program
2023-11-08 07:31
U:ADAP
News Release
200
Adaptimmune Reports Third Quarter Financial Results and Business Update
2023-11-08 07:06
U:ADAP
News Release
200
Adaptimmune Selects ADP-600 as Clinical Candidate for Best-in Class PRAME Strategy
2023-10-31 08:01
U:ADAP
News Release
200
Adaptimmune Reports Better Outcomes for People with Synovial Sarcoma who Received Afami-cel Compared to Historical Control
2023-10-31 08:01
U:ADAP
News Release
200
Adaptimmune Reports Positive Data with Lete-cel[1] from an Interim Analysis of the Pivotal IGNYTE-ESO Trial for People with Synovial Sarcoma or MRCLS
2023-10-25 08:07
U:ADAP
News Release
200
Adaptimmune to Report Q3 2023 Financial and Business Updates on Wednesday, November 8, 2023
2023-10-23 04:16
U:ADAP
News Release
200
Next-Generation TCR T-cell Therapy (ADP-A2M4CD8) Demonstrates Strong Efficacy in a Broad Range of Solid Tumors; Adaptimmune Presents Data Update from its SURPASS trial at ESMO
2023-09-11 08:01
U:ADAP
News Release
200
Dr. Karen Chagin Joins Adaptimmune as Senior Vice President of Early-Stage Development
2023-08-09 07:30
U:ADAP
News Release
200
Adaptimmune Reports Second Quarter Financial Results and Business Update
2023-08-03 13:25
U:ADAP
News Release
200
Adaptimmune to Report Q2 2023 Financial and Business Updates on Wednesday, August 9, 2023
2023-06-01 15:30
U:ADAP
News Release
200
Adaptimmune Announces Completion of Strategic Combination with TCR2 Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company